ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0887

Identification of Rare Variants in Lupus-causing Genes in a Mixed Paediatric and Adult Connective Tissue Disease Cohort
Abstract Number: 0705

Identification of Risk Factors for Incident Cardiomyopathy in Patients with Systemic Sclerosis
Abstract Number: 1866

Identification of Sjögren’s Disease-Associated CD4+ T Cell Receptor (TCR) Motifs and Repertoire Landscape Through TCR Deep Sequencing
Abstract Number: 1664

Identification of Spatial Determinants of Treatment Response in Rheumatoid Arthritis Synovia
Abstract Number: 2641

Identification of Systemic Sclerosis Intrinsic Subtypes in the ASSET Clinical Trial Using PBC Gene Expression
Abstract Number: 2211

Identifying Clinical Predictors of Difficult-to-Treat Rheumatoid Arthritis Using Machine Learning-based Techniques
Abstract Number: 1971

Identifying Educational Opportunities Through Examination of Referrals to Rheumatology Musculoskeletal US Clinic
Abstract Number: 2626

Identifying Homogeneous Endophenotypes in Childhood-Onset Systemic Lupus Erythematosus with Similarity Network Fusion
Abstract Number: 1042

Identifying Patient Priorities for Patient-Reported Outcome Measures in Rheumatoid Arthritis: A Modified Delphi Consensus Study
Abstract Number: 0909

Identifying Predictive Serum Soluble Mediators Signatures Specific to ANA+ at Risk of SLE Individuals with Next Generation Proteomics
Abstract Number: 0353

Identifying Solutions to Address Racial and Ethnic Health Disparities in Lupus: A Consensus-Based Approach
Abstract Number: 2196

Identifying Specific Criteria for Juvenile Systemic Sclerosis: A Comparison of Adult and Pediatric Ratings
Abstract Number: 2642

Identifying Systemic Sclerosis Molecular Subtypes by Their Cellular Signature – Deconvoluting the Puzzle
Abstract Number: 0328

IFI27 Is Differentially Upregulated in Anti-MDA5 Dermatomyositis and Correlates with the Presence of Interstitial Lung Disease
Abstract Number: 1658

IGF1 Drives Wnt-induced Joint Damage and Is a Therapeutic Target for Osteoarthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].